Silverback Therapeutics Competitors and Similar CompaniesClear all
Silverback Therapeutics's competitors and similar companies include NovoCure, Gossamer Bio, Zymeworks and Coherus Oncology.
 Silverback Therapeutics Silverback Therapeutics is a biotech company developing treatments for cancer, fibrosis, and infectious diseases. |  NovoCure NovoCure is a company engaged in the development, manufacture, and commercialization of solutions for the treatment of solid tumors. |  Gossamer Bio Gossamer Bio is a company focused on the discovery and development of novel and differentiated therapeutic products, to address high unmet needs amongst various targeted patient populations. |  Zymeworks Zymeworks is a computational biotechnology company focused on optimizing therapeutic antibodies and other protein-based therapeutics. |  Coherus Oncology Coherus BioSciences is a biopharmaceutical company that focuses on the research, development, and commercialization of cancer treatments. | |
Founding Date | Founding Date 2016 | Founding Date 2000 | Founding Date 2015 | Founding Date 2003 | Founding Date 2010 |
Type | Type Public | Type Public | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations Seattle, US HQ | Locations San Diego, US HQ Dublin 2, IE | Locations Vancouver, CA HQ Seattle, US | Locations Redwood City, US HQ Camarillo, US | |
Employees | Employees 9067% increase | Employees 1,488 | Employees 11820% increase | Employees 45519% increase | Employees 14736% decrease |
Valuation ($) | Valuation ($) 550.4 m | Valuation ($) 1.8 b | Valuation ($) 208 m | Valuation ($) 973.3 m | Valuation ($) 85.6 m |
Financial | |||||
Revenue (est.) | Revenue (est.) $1.3m (FY, 2022) | Revenue (est.) $655.4m (FY, 2025) | Revenue (est.) $48.5m (FY, 2025) | Revenue (est.) $106m (FY, 2025) | Revenue (est.) $42.2m (FY, 2025) |
Cost of goods | Cost of goods N/A | Cost of goods $166.9m (FY, 2025) | Cost of goods N/A | Cost of goods N/A | Cost of goods $13.8m (FY, 2025) |
Gross profit | Gross profit N/A | Gross profit $488.5m (FY, 2025) | Gross profit N/A | Gross profit N/A | Gross profit $28.4m (FY, 2025) |
Net income | Net income ($34.7m) (FY, 2022) | Net income ($136.2m) (FY, 2025) | Net income ($170.4m) (FY, 2025) | Net income ($81.1m) (FY, 2025) | Net income $168m (FY, 2025) |
Operating ⚠ | |||||
Phase II Trials Products | Phase II Trials Products N/A | Phase II Trials Products 6 (FY, 2021) | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products 1 (FY, 2020) |
Phase III Trials Products | Phase III Trials Products N/A | Phase III Trials Products 3 (FY, 2021) | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products 1 (FY, 2020) |
Trials Products Approved | Trials Products Approved N/A | Trials Products Approved 3 (FY, 2021) | Trials Products Approved N/A | Trials Products Approved N/A | Trials Products Approved 1 (FY, 2020) |
Funding | |||||
Total funding raised | Total funding raised $ 211m | Total funding raised N/A | Total funding raised $ 480m | Total funding raised $ 125.9m | Total funding raised $ 174.5m |
For sources of this data, please see the company profile
View Company Profiles
NovoCure
HQ
Saint Helier, JE
Employees
1,488
NovoCure is a company engaged in the development, manufacture, and commercialization of solutions for the treatment of solid tumors.
View companyGossamer Bio
HQ
San Diego, US
Employees
118↑ 20% increase
Gossamer Bio is a company focused on the discovery and development of novel and differentiated therapeutic products, to address high unmet needs amongst various targeted patient populations.
View companyZymeworks
HQ
Vancouver, CA
Employees
455↑ 19% increase
Zymeworks is a computational biotechnology company focused on optimizing therapeutic antibodies and other protein-based therapeutics.
View companyCoherus Oncology
HQ
Redwood City, US
Employees
147↓ 36% decrease
Coherus BioSciences is a biopharmaceutical company that focuses on the research, development, and commercialization of cancer treatments.
View company